[Skip to Content]
[Skip to Content Landing]
October 14, 1974

Medical News

JAMA. 1974;230(2):189-202. doi:10.1001/jama.1974.03240020003001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


A review of preliminary results of adenine arabinoside studies  The Food and Drug Administration will soon be asked to consider adenine arabinoside for prescription use as an ophthalmic agent.The compound was synthesized in 1960 as a potential anti-cancer agent. It is an anti-metabolite purine nucleoside derived from Streptomyces antibioticus, and is chemically known as 9-B-D-arabinofuranosyladenine. The United States Adopted Names Council's generic name for the compound is vidarabine, but most often it is referred to as ara-A.There are two primary areas of clinical study with ara-A. One, sponsored by Parke, Davis & Co (which has the investigational new drug permit), centers on ocular herpesvirus infections—herpes keratitis and herpes uveitis. The other, supported by the National Institutes of Health (particularly the National Institute of Allergy and Infectious Diseases), involves systemic infections.On the basis of the clinical ara-A studies in ocular herpes, Parke-Davis now is preparing the new